Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension of ACT-385781A vs Flolan in PAH
NCT01105117Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2010
- Primary completion
- Jul 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of epoprostenol in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Number of Patients With Adverse Events Leading Discontinuation of Study Treatment up to 39 days and Number of Deaths up to 39 days. Started May 2010; status: completed.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01105117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105117.